Nabriva Therapeutics (NBRV) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock NBRV vs. DRUG, ACRS, GALT, TIL, SLS, ALMS, CYBN, VYGR, BDTX, and IPHAShould you be buying Nabriva Therapeutics stock or one of its competitors? The main competitors of Nabriva Therapeutics include Bright Minds Biosciences (DRUG), Aclaris Therapeutics (ACRS), Galectin Therapeutics (GALT), Instil Bio (TIL), SELLAS Life Sciences Group (SLS), Alumis (ALMS), Cybin (CYBN), Voyager Therapeutics (VYGR), Black Diamond Therapeutics (BDTX), and Innate Pharma (IPHA). These companies are all part of the "pharmaceutical products" industry. Nabriva Therapeutics vs. Its Competitors Bright Minds Biosciences Aclaris Therapeutics Galectin Therapeutics Instil Bio SELLAS Life Sciences Group Alumis Cybin Voyager Therapeutics Black Diamond Therapeutics Innate Pharma Bright Minds Biosciences (NASDAQ:DRUG) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk. Which has more volatility and risk, DRUG or NBRV? Bright Minds Biosciences has a beta of -6.01, meaning that its share price is 701% less volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Which has higher valuation and earnings, DRUG or NBRV? Bright Minds Biosciences has higher earnings, but lower revenue than Nabriva Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBright Minds BiosciencesN/AN/A-$2.06M-$0.36-83.00Nabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/A Do insiders and institutionals believe in DRUG or NBRV? 40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by company insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media favor DRUG or NBRV? In the previous week, Bright Minds Biosciences had 2 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 2 mentions for Bright Minds Biosciences and 0 mentions for Nabriva Therapeutics. Bright Minds Biosciences' average media sentiment score of 0.81 beat Nabriva Therapeutics' score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Overall Sentiment Bright Minds Biosciences Positive Nabriva Therapeutics Neutral Do analysts rate DRUG or NBRV? Bright Minds Biosciences currently has a consensus target price of $83.25, indicating a potential upside of 178.61%. Given Bright Minds Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Bright Minds Biosciences is more favorable than Nabriva Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is DRUG or NBRV more profitable? Bright Minds Biosciences has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Bright Minds Biosciences' return on equity of -14.56% beat Nabriva Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bright Minds BiosciencesN/A -14.56% -14.29% Nabriva Therapeutics -148.11%-365.53%-135.81% SummaryBright Minds Biosciences beats Nabriva Therapeutics on 13 of the 16 factors compared between the two stocks. Get Nabriva Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBRV vs. The Competition Export to ExcelMetricNabriva TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.46M$783.82M$5.57B$9.42BDividend YieldN/A4.84%4.05%3.99%P/E Ratio0.001.4028.0920.08Price / SalesN/A25.01403.9184.07Price / CashN/A19.5636.1958.45Price / BookN/A6.928.615.83Net Income-$57.19M-$4.13M$3.24B$258.27M Nabriva Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070DRUGBright Minds Biosciences2.3236 of 5 stars$25.70-1.7%$83.25+224.0%+2,591.9%$180.89MN/A-71.37N/ANews CoverageACRSAclaris Therapeutics1.6905 of 5 stars$1.67+1.5%$8.71+423.4%+20.0%$180.29M$17.78M-1.20100GALTGalectin Therapeutics2.4958 of 5 stars$2.82+3.1%$6.00+112.5%+8.9%$178.48MN/A-3.929Gap UpTILInstil Bio2.4269 of 5 stars$27.17-1.6%$119.00+338.1%+135.1%$178.18MN/A-2.27410Positive NewsSLSSELLAS Life Sciences Group1.6374 of 5 stars$1.80-3.0%$7.00+290.0%+56.6%$178.11M$1M-4.7010ALMSAlumis3.1115 of 5 stars$3.33+0.3%$22.86+586.4%-69.5%$177.87MN/A0.00N/ACYBNCybin2.7164 of 5 stars$7.57-5.7%$85.00+1,022.6%N/A$177.29MN/A-1.7650VYGRVoyager Therapeutics3.8888 of 5 stars$3.19+0.5%$13.39+320.4%-63.0%$176.25M$66.96M-2.18100BDTXBlack Diamond Therapeutics2.2224 of 5 stars$3.12-1.1%$12.80+310.9%-48.6%$175.98MN/A51.5890IPHAInnate Pharma2.4377 of 5 stars$1.90-1.0%$11.00+478.9%-10.9%$175.14M$21.77M0.00220Positive News Related Companies and Tools Related Companies DRUG Alternatives ACRS Alternatives GALT Alternatives TIL Alternatives SLS Alternatives ALMS Alternatives CYBN Alternatives VYGR Alternatives BDTX Alternatives IPHA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBRV) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBitcoin just humbled Jeff BezosBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nabriva Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Nabriva Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
